Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers - Additional Information (Detail)

v3.10.0.1
Revenues from Contracts and Significant Customers - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Return Reserve $ 500,000 $ 300,000   $ 500,000 $ 300,000
Revenue from Contract with Customer, Including Assessed Tax 5,168,000     17,366,000  
License and Service [Member]          
Revenue from Contract with Customer, Including Assessed Tax 5,000     500,000  
Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Revenue Recognition Milestone Method Payments $ 5,000 200,000   400,000 800,000
Payment Of Upfront Licensing Fee       $ 1,000,000  
Research And Development Cost Shared Percentage 50.00%     50.00%  
Checkpoint Collaboration Agreement with TGTX NeuPharma, Inc. and TGTX [Member]          
Revenue Recognition Milestone Method Payments $ 0   $ 100,000 $ 31,000 500,000
Checkpoint Collaboration Agreement With TGTX Related To DanaFarber License [Member]          
Revenue Recognition Milestone Method Payments 0 46,000   44,000 84,000
Customer One [Member]          
Accounts Receivable, Net 9,000,000 1,700,000   9,000,000 1,700,000
Revenue from Contract with Customer, Including Assessed Tax 10,900,000 3,000,000   22,500,000 6,700,000
Customer Two [Member]          
Accounts Receivable, Net 1,400,000 1,500,000   1,400,000 1,500,000
Revenue from Contract with Customer, Including Assessed Tax   $ 1,700,000   7,300,000 $ 6,000,000
Checkpoint Therapeutics, Inc [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Revenue Recognition Milestone Method Payments       500,000  
First Commercial Sale Milestone [Member] | Checkpoint Therapeutics, Inc [Member]          
Revenue Recognition Milestone Method Payments       21,500,000  
Additional Sales Milestone [Member] | Checkpoint Therapeutics, Inc [Member]          
Revenue Recognition Milestone Method Payments Due       60,000,000  
Commercial Sales In Specified Territories [Member] | Checkpoint Therapeutics, Inc [Member]          
Revenue Recognition Milestone Method Payments Due       14,500,000  
Successful Achievement Of One Preclinical Milestone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Revenue Recognition Milestone Method Payments Due       25,500,000  
Clinical Development And Regulatory Milestones [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Revenue Recognition Milestone Method Payments Due       87,200,000  
Clinical Development And Regulatory Milestones [Member] | Checkpoint Therapeutics, Inc [Member]          
Revenue Recognition Milestone Method Payments Due       7,000,000  
Five Regulatory Approvals And First Commercial Sales [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Maximum Potential Milestone Payments 61,700,000     61,700,000  
Sale Millstone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]          
Maximum Potential Milestone Payments $ 89,000,000     $ 89,000,000